Development of antiviral therapy for severe acute respiratory syndrome
A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2005 |
|---|---|
| Erschienen: |
2005 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Antiviral research - 66(2005), 2-3 vom: 20. Juni, Seite 81-97 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cinatl, Jindrich [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 19.09.2005 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM155233653 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM155233653 | ||
| 003 | DE-627 | ||
| 005 | 20231223071705.0 | ||
| 007 | tu | ||
| 008 | 231223s2005 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0518.xml |
| 035 | |a (DE-627)NLM155233653 | ||
| 035 | |a (NLM)15878786 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cinatl, Jindrich |c Jr |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of antiviral therapy for severe acute respiratory syndrome |
| 264 | 1 | |c 2005 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 19.09.2005 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Michaelis, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Hoever, Gerold |e verfasserin |4 aut | |
| 700 | 1 | |a Preiser, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Doerr, Hans Wilhelm |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antiviral research |d 1983 |g 66(2005), 2-3 vom: 20. Juni, Seite 81-97 |w (DE-627)NLM012601756 |x 1872-9096 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2005 |g number:2-3 |g day:20 |g month:06 |g pages:81-97 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2005 |e 2-3 |b 20 |c 06 |h 81-97 | ||